# Prexasertib

Source: https://onco.cc/drugs/prexasertib/  
OnCo record `prexasertib` (Treatment). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

Prexasertib is an experimental small molecule from Acrivon Therapeutics, in phase 2 trials for endometrial cancer, platinum-resistant ovarian cancer and head and neck squamous cell carcinoma.

## Summary

Prexasertib (ACR-368, LY2606368) is a small molecule from Acrivon Therapeutics, with Eli Lilly as licensor (originator. A selective inhibitor of the DNA damage response checkpoint kinases CHK1 and CHK2. Acrivon uses its OncoSignature test on a tumour biopsy to pick patients predicted to respond. Its furthest stage is phase 2, for endometrial cancer, platinum-resistant ovarian cancer and head and neck squamous cell carcinoma. ClinicalTrials.gov registers it in 2 studies linked below. Registrational-intent phase 2b in endometrial cancer; Acrivon plans to start a phase 3 confirmatory trial in the first half of 2027 (Q2 2026 results release, 12 August 2026). Whether it works in people has not been established unless a trial below reports it.

## Fields

- Kind: Treatment
- Status: phase-2
- Last checked: 2026-11-03
- Also known as: ACR-368; LY2606368
- Tags: pipeline; ctgov-ingest
- Code: ACR-368
- Modality: Small molecule
- Mechanism: A selective inhibitor of the DNA damage response checkpoint kinases CHK1 and CHK2. Acrivon uses its OncoSignature test on a tumour biopsy to pick patients predicted to respond.

## Sources

- Acrivon Therapeutics: acrivon.com: https://acrivon.com/pipeline/
- Acrivon Therapeutics: acrivon.com: https://acrivon.com/pipeline/
- Acrivon Therapeutics: sec.gov: https://www.sec.gov/Archives/edgar/data/1781174/000119312526346859/acrv-ex99_1.htm
- Acrivon Therapeutics: clinicaltrials.gov: https://clinicaltrials.gov/api/v2/studies/NCT06597565
- ClinicalTrials.gov: trials of ACR-368: https://clinicaltrials.gov/search?intr=ACR-368

## Connected records

- cancers: [Endometrial cancer](https://onco.cc/cancers/endometrial/), [Head and neck squamous cell carcinoma](https://onco.cc/cancers/head-and-neck/)
- targets: [CHEK1](https://onco.cc/targets/chek1/), [CHEK2](https://onco.cc/targets/chek2/)
- companies: [Acrivon Therapeutics](https://onco.cc/companies/acrivon-therapeutics/)
- trials: [A Phase 2 Study of ACR-368 in Endometrial Adenocarcinoma](https://onco.cc/trials/nct05548296/), [A Phase II Study of ACR-368 and Low Dose Gemcitabine in R/M HNSCC](https://onco.cc/trials/nct06597565/)

---
JSON: https://onco.cc/api/v1/entities/prexasertib.json